Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a fixed-dose combination of three active pharmaceutical ingredients: - **Lornoxicam** is a non-steroidal anti-inflammatory drug (NSAID) from the oxicam class, which works by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the synthesis of prostaglandins responsible for pain and inflammation. - **Paracetamol** (also known as acetaminophen) is an analgesic and antipyretic that acts primarily in the central nervous system to inhibit prostaglandin synthesis, providing pain relief and fever reduction. - **Thiocochicoside** is a muscle relaxant that acts on the central nervous system, likely through modulation of GABA-A receptors or glycine receptors, leading to reduced muscle spasms. The combination provides multimodal management for musculoskeletal pain conditions by addressing inflammation, nociceptive pain, and muscle spasm. It is typically used for acute painful musculoskeletal disorders such as back pain, sprains, joint pain with associated muscle spasm, arthritis flare-ups with significant muscular involvement, or post-operative musculoskeletal discomfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lornoxicam + paracetamol + thiocochicoside.